Skip to main content

Table 1 Perioperative characteristics of patients scheduled for on-pump cardiac surgery

From: Polymorphisms on PAI-1 and ACE genes in association with fibrinolytic bleeding after on-pump cardiac surgery

Characteristics

PAI-1 -844 A/G

ACE Intron 16 I/D

Genotype

G/G

A/G

A/A

I/I

I/D

D/D

Number of patients, n

22

387

23

22

42

19

Demographic data

 Age, yr

61 ± 11

68 ± 10

67 ± 11

68 ± 10

66 ± 10

63 ± 14

 Male sex, n (%)

15 (68)

16 (42)

11 (48)

9 (41)*

23 (55)* **

10 (53)**

 BMI, kg/m2

28 ± 5

28 ± 8

27 ± 5

27 ± 5

28 ± 5

27 ± 4

 EF, (%)

57 ± 8

55 ± 8

56 ± 7

58 ± 6

55 ± 9

55 ± 7

Type of surgery, n (%)

 CABG, n (%)

11 (50)

15 (40)

8 (35)

8 (36)

18 (43)

8 (42)

 Valve, n (%)

8 (36)

13 (34)

10 (43)

9 (41)

13 (31)

9 (47)

 Mixed, n (%)

3 (14)

10 (26)

5 (22)

5 (23)*

11 (26)* **

2(11)**

Surgical variables

 CPB duration (min)

110 ± 42

106 ± 42

99 ± 37

101 ± 47

105 ± 39

109 ± 37

 Aorta oclusion time (min)

69 ± 30

65 ± 25

63 ± 11

64 ± 27

65 ± 27

69 ± 29

 Reperfusion time (min)

33 ± 12

33 ± 15

33 ± 16

29 ± 13

36 ± 17

33 ± 9

 CPB priming volume, ml

1864 ± 543

1509 ± 516

1329 ± 440

1379 ± 462

1548 ± 556

1544 ± 482

 Cardioplegia, ml

1872 ± 587

1673 ± 516

1886 ± 674

1647 ± 523

1833 ± 655

1836 ± 478

Preoperative parameters

 Hemoglobin, g/dL

136 ± 15

139 ± 13

131 ± 18

132 ± 17

137 ± 16

138 ± 12

 Platelet count, × 109/L

221 ± 67

215 ± 50

215 ± 63

211 ± 45

218 ± 65

220 ± 58

 Prothrombin time, %

84 ± 15

90 ± 14

92 ± 12

94 ± 15

89 ± 13

85 ± 14

 Fibrinogen, g/L

4.4 ± 1.3

4.6 ± 1.2

4.7 ± 1.5

4.5 ± 1.2

4.6 ± 1.2

4.7 ± 3.7

  1. Data presented as the mean ± standard error of the mean
  2. PAI-1 Plasminogen activator inhibitor type-1, A Adenosine, G Guanine, ACE Angiotensin converting enzyme, I Insertion, D Deletion, n Number of patients, BMI Body mass index, EF Ejection fraction, CABG Coronary artery bypass grafting, CPB Cardiopulmonary bypass. *P < 0.05 between ACE Intron 16 I/I and I/D genotypes;
  3. **P < 0.05 between ACE Intron 16 D/D andI/D genotypes